Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Postoperative intravenous ferric carboxymaltose for anaemia after major abdominal surgery
ACTRN12623000669695Phase 4Withdrawn
- Sponsor
- Veritas Collaborative
- Start
- Sep 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of ferric carboxymaltose in anaemia (2 arms), sponsored by Veritas Collaborative. Primary endpoints: Change in haemoglobin concentration and Recruitment rate per site. Planned start Sep 2023; status: withdrawn.
02
Drugs
ferric carboxymaltose
03
Conditions
anaemia
Beyond the preview
Go deeper on ACTRN12623000669695.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12623000669695.